For the ARE-bla-mut assay, a stable ß-lactamase reporter cell line utilizing the ARE mutant enhancer/promoter element derived from the ARE mutant reporter construct was constructed as follows: The ß-lactamase open reading frame from pcDNA6.2-cGeneBlazer (Invitrogen) was isolated by PCR using the following primers:
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while columns 2 and 4 contained 12 µM ß-napthoflavone and 6 µM ß-napthoflavone, respectively, in the ARE-luc assay. Supplemental Material, Table S3 : Activities and potencies for 34 compounds overlapping ARE-bla and ARE-luc assays in the primary qHTS screen (17) 2 (10) 26 (30) Supplemental Material, Figure S1 : Heat map of all follow-up compounds tested in ARE-bla, ARE-bla-mut, and ARE-luc assays. Activity shown was based on log10transformed compound EC 50 values across all assays. Each row represents a compound and each column represents a follow-up assay. The heat maps were clustered by pattern and colored based on compound activity, where activity in the assay is colored red, less conclusive activators are colored a lighter shade of red, and inactive compounds are white.
Chemical Analysis for Compound Purity
Supplemental Material, Figure S2 : A flowchart of identification of ARE inducers in multiple assay formats using qHTS. One hundred and forty-one compounds were commonly active between the ARE-bla and ARE-luc assays in the primary screen and 34 of those compounds were high quality actives with curve classes 1.1, 2.1, 2.1, and 2.2. These compounds, along with compounds with various activity profiles across different SAR clusters were chosen for followup testing, resulting in 63 compounds. Quality control analysis confirmed the identity of 50/63 compounds, hence these were re-tested in the ARE-bla, ARE-luc, ARE-bla-mut and luciferase inhibition (latter 2 assays not shown in the diagram) assays. Forty-seven and 45 compounds confirmed activity in the ARE-bla and ARE-luc assays, respectively.
